Correction to: LncRNA SNHG1 contributes to sorafenib resistance by activating the Akt pathway and is positively regulated by miR-21 in hepatocellular carcinoma cells (Journal of Experimental & Clinical Cancer Research, (2019), 38, 1, (183), 10.1186/s13046-019-1177-0)

4Citations
Citations of this article
1Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Following publication of the original article [1], the authors identified some minor errors in Figs. 3 and 4, specifically: • In Fig. 3a, the cytometrical dot plots originally contained errors • In Fig. 4f, an incorrect image was originally used for the anti-SNHG1-treated tumor sections ( 1st row, 3rd column) The authors provided the Journal with the original data. The corrected figures are given here. The corrections do not have any effect on the final conclusions of the paper. The original article has been corrected.

Cite

CITATION STYLE

APA

Li, W., Dong, X., He, C., Tan, G., Li, Z., Zhai, B., … Sun, X. (2021, December 1). Correction to: LncRNA SNHG1 contributes to sorafenib resistance by activating the Akt pathway and is positively regulated by miR-21 in hepatocellular carcinoma cells (Journal of Experimental & Clinical Cancer Research, (2019), 38, 1, (183), 10.1186/s13046-019-1177-0). Journal of Experimental and Clinical Cancer Research. BioMed Central Ltd. https://doi.org/10.1186/s13046-021-02183-3

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free